Hørsholm, Denmark, 19 May 2026 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate in two upcoming investor events in May 2026: the BioStock Global Forum in Lund, Sweden, and a virtual presentation of the Company’s Q1 2026 interim report hosted by H.C. Andersen Capital.
These events provide an opportunity to present ExpreS2ion’s technology platform and development pipeline to investors and industry participants. More details, including event registration information, are available on the Company’s website and via the links below. To arrange a meeting at these events, please contact us at partnering@expres2ionbio.com or investor@expres2ionbio.com.
21 May 2026 | BioStock Global Forum
Lund, Sweden
ExpreS2ion will participate in the BioStock Global Forum 2026 in Lund, Sweden. The forum brings together Nordic and international life science companies, investors and industry representatives for company presentations and discussions on innovation, financing and growth across the sector.
CEO Bent Frandsen will present ExpreS2ion and provide a company update, including recent progress across the Company’s technology platforms and development pipeline in oncology and infectious diseases. For more information, please visit the official conference page.
28 May 2026 | Q1 2026 Interim Report Presentation
Virtual, 10:00 CET
CEO Bent Frandsen and CFO Keith Alexander will present ExpreS2ion’s Q1 2026 interim report at a virtual investor event hosted by H.C. Andersen Capital. The presentation will cover the Company’s clinical progress, partnered programmes, platform activities and financial position.
Investors may register for the webcast and submit questions in advance via the Inderes platform. The event is free and open to all investors.
Certified Adviser
Redeye Nordic Growth AB
For further information about ExpreS2ion, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
E-mail: investor@expres2ionbio.com
About ExpreS2ion
ExpreS2ion is a biotechnology company focused on the development of innovative active immunotherapies and vaccines for cancer and infectious diseases. The company has developed the ExpreS2™ platform, a proprietary protein expression technology used across more than 500 recombinant protein and virus-like particle (VLP) projects spanning research, diagnostics, and therapeutic development. Proteins produced using the ExpreS2 platform are being evaluated in multiple clinical programmes worldwide. The platform has also been applied in partnered development programmes that have progressed into late-stage clinical evaluation, including Phase III studies that have met their primary endpoints. The platform, marketed as GlycoX-S2™, includes functionally modified glycosylation variants designed to enhance immunogenicity and pharmacokinetics. ExpreS2ion develops novel VLP-based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. ExpreS2ion Biotech AB is listed on Nasdaq First North Growth Market. For additional information, please visit www.expres2ionbio.com.